Core Insights - Vermilion Energy Inc. has successfully closed the sale of Saskatchewan assets for gross proceeds of $415 million, which is part of its strategic plan to enhance its asset portfolio [1] - The sold assets include approximately 10,500 barrels of oil equivalent per day (boe/d), with 86% being oil and liquids, located in Saskatchewan and Manitoba [1] - The net cash proceeds from this transaction will improve Vermilion's balance sheet and provide greater capital allocation flexibility for its core Canadian and European assets [1] Company Overview - Vermilion is a global gas producer focused on creating value through the acquisition, exploration, and development of liquids-rich natural gas in Canada and conventional natural gas in Europe [2] - The company aims to optimize low-decline oil assets, which contributes to generating significant free cash flow through exposure to global commodity prices [2] Corporate Priorities - The company's priorities are health and safety, environmental protection, and profitability, emphasizing the importance of public safety and natural surroundings [3] - Vermilion also focuses on strategic community investment in its operating areas [3]

TUSTIN, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- A group of holders of the Series C Preferred Stock of Freeze Tag, Inc. (OTC:FRZT) (the “Company”), representing an aggregate of 65.92% of the total voting power of the Company, announced today that, pursuant to Section 141(k) and Section 228 of the Delaware General Corporation Law (the “DGCL”), they have approved and delivered to the Company a Written Consent removing Craig Holland and Mick Donahoo as members of the Board of Directors (the “Corporate Action” ...

Core Viewpoint - Morgan Stanley is expected to report Q2 earnings on July 16, following a strong Q1 performance with record net revenues of $17.739 billion, indicating robust momentum in its operations [1]. Group 1: Financial Performance - The previous quarter showcased record net revenues of $17.739 billion for Morgan Stanley [1]. - The Institutional Securities segment experienced rapid growth, contributing to the overall strong performance [1]. Group 2: Investment Insights - The analysis emphasizes the importance of identifying stocks that exhibit both growth and quality factors, suggesting a focus on companies with strong growth narratives supported by solid financial statements [1].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Red Cat Holdings, Inc. regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 18, 2022, to January 15, 2025 [3]. - Allegations include that the company overstated the production capacity of the Salt Lake City Facility and the value of the U.S. Army's Short Range Reconnaissance Program of Record Tranche 2 contract, leading to materially false and misleading public statements [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 22, 2025, to potentially be appointed as lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements and omissions concerning the safety of its Enfamil formula for preterm infants [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of necrotizing enterocolitis (NEC) in preterm infants, which was not disclosed [3]. - The lawsuit claims that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [3]. Group 2: Shareholder Actions and Deadlines - Shareholders are encouraged to register for the class action by August 4, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered losses due to deceit and illegal business practices [5]. - The firm emphasizes the importance of responsible business practices and corporate citizenship [5]. - The firm seeks recovery for investors affected by misleading statements that led to artificial inflation of the company's stock [5].

Core Viewpoint - Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) is facing a class action lawsuit due to allegations of misleading statements regarding its business model and growth potential during the pandemic [3][5]. Allegations - The pandemic-related growth experienced by Petco was deemed unsustainable, particularly its focus on premium pet food sales [3]. - The strength of Petco's differentiated product strategy was overstated, leading to inflated expectations of sustainable growth [3]. - Defendants allegedly downplayed the severity of issues affecting the company and the necessary changes to address them, which could negatively impact comparable sales [3]. - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Class Action Details - The class period for the lawsuit is from January 14, 2021, to June 5, 2025 [3]. - Shareholders are encouraged to register for the class action by the deadline of August 29, 2025, to potentially become lead plaintiffs [4]. - Participation in the case does not incur any costs or obligations for shareholders [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of PepGen Inc. regarding a class action lawsuit due to alleged misleading statements about the company's lead product candidate, PGN-EDO51, and its clinical study [1][3]. Group 1: Allegations - The complaint alleges that during the class period from March 7, 2024, to March 3, 2025, PepGen's statements regarding PGN-EDO51 were materially false and misleading [3]. - Specific allegations include that PGN-EDO51 was less effective and safe than claimed, and that the phase two CONNECT2 study was dangerous or deficient for FDA approval [3]. - As a result of these issues, it is claimed that PepGen was likely to halt the CONNECT2 study, and the clinical, regulatory, and commercial prospects of PGN-EDO51 were overstated [3]. Group 2: Class Action Details - Shareholders are encouraged to register for the class action by the deadline of August 8, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. - There is no cost or obligation for shareholders to participate in this case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of DoubleVerify Holdings, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical information during the class period from November 10, 2023, to February 27, 2025 [1][3]. Allegations - The complaint alleges that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited, impacting its competitive position against platforms like Meta and Amazon [3]. - It is claimed that the monetization of DoubleVerify's Activation Services was hindered by the high costs and time required to develop technology for closed platforms, which were not adequately disclosed to investors [3]. - The lawsuit states that it would take several years for DoubleVerify's Activation Services related to certain closed platforms to become profitable [3]. - Competitors were reportedly better positioned to integrate AI into their offerings on closed platforms, negatively affecting DoubleVerify's competitiveness and profitability [3]. - The company allegedly overbilled customers for ad impressions served to bots operating from known data centers [3]. - The risk disclosures provided by DoubleVerify were said to be materially false and misleading, as they downplayed already materialized adverse facts [3]. - As a result of these issues, the positive statements made by the defendants regarding the company's business and prospects were claimed to be materially false or misleading [3]. Next Steps for Shareholders - Shareholders who purchased shares of DoubleVerify during the specified class period are encouraged to register for the class action by July 21, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. Specific allegations include: - Significant safety risks associated with ELEVIDYS were not disclosed [3]. - Trial protocols failed to identify severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action. The deadline for seeking lead plaintiff status is August 25, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud. The firm aims to ensure companies engage in responsible business practices [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of 3D Systems Corporation regarding a class action lawsuit due to alleged misleading statements and omissions made by the company during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from August 13, 2024, to May 12, 2025 [3]. - Allegations include that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [3]. - Additionally, the updated milestone criteria in the partnership with United Therapeutics Corporation are claimed to negatively impact the company's regenerative medicine program revenue [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by the deadline of August 12, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors affected by deceit and illegal business practices, seeking recovery for losses incurred due to misleading statements by companies [5].